Gold prices bounce off 3-week lows; demand likely longer term
David Mott, a director at Ardelyx, Inc. (NASDAQ:ARDX), recently acquired 200,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transaction, executed on June 9, 2025, was valued at approximately $737,260, with shares purchased at a weighted average price of $3.6863. The purchase comes as InvestingPro data shows Ardelyx trading near $3.70, with analyst price targets ranging from $8 to $15, suggesting significant upside potential. The shares were acquired in multiple trades, with prices ranging from $3.61 to $3.75. Following this transaction, Mott holds a total of 2,696,871 shares directly. Additionally, he holds 87,566 shares for the benefit of entities associated with New Enterprise Associates, although he disclaims beneficial ownership of these shares except to the extent of his actual pecuniary interest. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 4.12 and has achieved impressive revenue growth of 127% over the last twelve months. Discover more insights and 7 additional ProTips with an InvestingPro subscription.
In other recent news, Ardelyx Inc . reported its first-quarter 2025 earnings, revealing a net loss of $0.17 per share, which fell short of the anticipated loss of $0.11 per share. The company’s revenue reached $74.1 million, missing the expected $78.09 million, despite a 61% year-over-year growth. Ardelyx’s products, IBSRELA and XPOVIO, saw significant sales growth, with IBSRELA netting $44.4 million and XPOVIO $23.4 million, but these figures did not meet consensus estimates. Analyst firm Raymond (NSE:RYMD) James downgraded Ardelyx’s stock rating from "Strong Buy" to "Outperform," citing weaker than expected net sales and increased SG&A expenses as reasons for concern. The company remains optimistic, maintaining its 2025 guidance for IBSRELA net sales between $240 million and $250 million and peak sales for XPOVIO at $750 million. Ardelyx also presented new data on its drug IBSRELA at the Digestive Disease Week Conference, emphasizing its potential benefits for patients with irritable bowel syndrome with constipation. Additionally, Ardelyx announced key executive appointments, promoting Mike Kelliher to Chief Business Officer and hiring James P. Brady as Chief Human Resources Officer to support its growth and expansion strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.